Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Hypercortisolism in Difficult-to-Control Cardiometabolic Conditions: Type 2 Diabetes and Hypertension

Reporter: Aviva Lev-Ari, PhD, RN

Do you have patients who are adherent with their medications yet still have uncontrolled type 2 diabetes (T2D) and hypertension? Data from the CATALYST trial presented in 2024 found that 24% of patients with difficult-to-control T2D had hypercortisolism. In a subanalysis of the CATALYST trial, drug-resistant hypertension was present in a third of patients with difficult-to-control T2D. Therefore, we are beginning to understand that excess cortisol could be driving difficult-to-control cardiometabolic conditions. Learn how to screen patients who may have unrecognized hypercortisolism in this collection of education activities created by leading experts in the fields of cardiology, nephrology, diabetes, and endocrinology.

SOURCE

https://www.medscape.org/sites/advances/hypercortisolism?sso=true&uac=93761AJ&src=mkmcmr_driv_clinad_mscpedu